骨髓增生异常综合征和急性白血病病人血清TPO、LDH的测定及临床意义

本研究探讨骨髓增生异常综合征（MDS）和急性白血病（AL）病人血清血小板生成素（TPO）和乳酸脱氢酶（LDH）的含量及其临床意义。采用双抗体夹心酶联免疫吸附法，测定了25例MDS、40例急性白血病病人化疗前、骨髓抑制期及骨髓恢复期血清中TPO含量；同时用速率法（由L到P）测定上述病人血清乳酸脱氢酶水平，并以15例健康体检者上述指标作为正常对照。结果发现，ALL、AML和MDS病人治疗前血清中TPO、LDH水平均明显高于正常对照组，差异有显著性意义（q=7．2943—27．4149，P〈0．001），骨髓抑制期及恢复期患者血清TPO、LDH水平比治疗前明显降低（q=7．2943—25．9396，P〈0．001），与正常对照组比较无显著性差异（q=1．4816—2．5657，P〉0．05）。结论：血清TPO、LDH水平与恶性血液病患者疾病恶性程度密切相关，检测患者血清TPO、LDH水平可用于恶性血液病的疗效观测。

Measurement and Clinical Significance of Serum TPO and LDH Levels in Patients with Myelodysplastic Syndrome and Acute Leukemia

The aim of this study was to explore the measurement and clinical significance of serum thrombopoietin (TPO) and lactate dehydrogenase (LDH) levels in patients with myelodysplastic syndrome ( MDS ) and acute leukemia (AL). The levels of serum TPO and lactate dehydrogenase in 25 patients with MDS and 40 patients with AL were measured by using sandwich ELISA and velocity methods before chemotherapy, at the stages of bone marrow depression and bone marrow recovery, respectively. The levels of serum TPO and LDH in 15 healthy controls were also measured. The results indicated that the serum TPO and LDH levels in ALL, AML and MDS patients before chemotherapy were significantly higher than those in healthy controls, the differences were statistically significant (q =7.2943 -27.4149, p ＜0. 001 ). The serum TPO and LDH levels in the patients at the stages of bone marrow depression or bone marrow recovery were significantly lower than those in patients before treatment ( q = 7. 2943 - 25. 9396, p ＜ 0.001 ), but there were no significant differences as compared with healthy controls(q = 1. 4816-2.5657,p ＞0.05 ). It is concluded that there is a strong correlation between serum TPO, LDH levels and the status of patients with hematologic malignancies, suggesting that TPO and LDH levels can be used for evaluation of therapeutic effect in hematologic malignancies.